Skip to main content

Table 1 Main characteristics of patients and treatment plan.

From: On the performances of Intensity Modulated Protons, RapidArc and Helical Tomotherapy for selected paediatric cases

  Patient 1 Patient 2 Patient 3 Patient 4 Patient 5
Patient Male, 12 y.o. Female, 8 y.o. Female, 5 y.o. Female, 13 y.o. Female, 8 y.o.
Diagnosis Ewing Sarcoma extraosseous, intrathoracic Rhabdomyosarcoma mediastinum, stage III Metastasis of base of skull with bone, para-nasal and lef eye infiltration from Nefroblastoma of right kidney Rhabdomyosarcoma anus.
Metastasis lymphnodes intrapelvic, inguinal and osseous
Wilm's tumour of the left kidney.
(Multiple lung metastasis).
Multiple liver metastasis
Status After chemotherapy + surgery + chemotherapy After chemotherapy After chemotherapy + right nefrectomy After chemotherapy After chemotherapy + left nefrectomy + chemo-radiotherapy for lung metastasis
Radiotherapy dose
Prescription
PTV = 28 × 1.9 = 53.2 Gy
PTV scar = 28 × 1.6 = 44.8 Gy
PTVII = 25 × 1.98 = 49.5 Gy
PTVI = 25 × 1.80 = 45.0 Gy
PTVII = 17 × 2.5 = 42.5 Gy
PTVI = 17 × 1.8 = 30.6 Gy
PTVII = 25 × 1.98 = 49.5 Gy
PTVI = 25 × 1.80 = 45 Gy
PTV = 15 × 1.2 18 Gy
Target volumes PTV = 564 cm3
PTV scar = 14 cm3
PTVI = 109 cm3
PTVII = 72 cm3
PTVI = 1436 cm3
PTVII = 104 cm3
PTVI = 618 cm3
PTVII = 193 cm3
PTV = 1234 cm3
Organs at risk dose objectives Lung1 < 15 Gy
Heart1 < 30 Gy
Vertebra1 < 20 Gy
Spinal cord2 < 45 Gy
Lung1 < 15 Gy
Heart1 < 30 Gy
Vertebra1 < 20 Gy
Spinal cord2 < 45 Gy
Right eye1 < 40 Gy
Left eye (blind)1 < 50 Gy
Lens1 < 10 Gy
Spinal cord2 < 45 Gy
Rectum1 < 40 Gy
Bladder1 < 30 Gy
Uterus1 < 20 Gy
Femural heads1 < 20 Gy
Kidney1 < 10 Gy
Techniques RA: 2 copl arcs, HDMLC
HT: Fld s. 2.5 cm, pitch 0.43
IMP: 3 fields
RA: 2 copl arcs, HDMLC
HT: Fld s. 2.5 cm, pitch 0.43
IMP: 2 fields
RA: 2 copl arcs, MLC120
HT: Fld s. 2.5 cm, pitch 0.43
IMP: 2 fields
RA: 2 non copl arcs, MLC120
HT: Fld s. 2.5 cm, pitch 0.43
IMP: 6 fields
RA: 2 non copl arcs, MLC120
HT: Fld s. 2.5 cm, pitch 0.43
IMP: 2 fields
Delivery time
MU
RA: 129 s, MU: 479
HT: 387 s MU: NA
IMP: NA MU: NA
RA: 123 s MU: 370
HT: 146 s MU: NA
IMP: NA MU: NA
RA: 129 s MU: 538
HT: 341 s MU: NA
IMP: NA MU: NA
RA: 127 s MU: 527
HT: 334 s MU: NA
IMP: NA MU: NA
RA: 129 s MU: 483
HT: 255 s MU: NA
IMP: NA MU: NA
  1. 1: mean dose; 2: maximum dose